Özet:

Objective: Increasing antibiotic resistance makes treatment of Gram-negative pathogens such as Pseudomonas aeruginosa and Klebsiella spp. difficult and increases mortality and morbidity. Therefore, new antibiotics that can be effective against resistant strains are being developed. The efficacy of ceftazidime/avibactam has been proven in Gram negative bacteria producing serine carbapenemase. In this study, we aimed to evaluate ceftazidime/avibactam, aminoglycoside, fluoroquinolone susceptibility in carbapenem-resistant Pseudomonas aeruginosa and Klebsiella spp. isolated from intensive care unit patients. Material and Methods: Between September 2022 and June 2023, 43 carbapenem resistant Klebsiella spp. and Pseudomonas spp. strains isolated from patients hospitalized in the intensive care unit were included in the study. Ceftazidime/avibactam susceptibilities were determined by disk diffusion test. The results were interpreted according to the European Committee on Antimicrobial Susceptibility Testing criteria. The statistical package for the Social Sciences version 24.0 (IBM SPSS Inc, Chicago) was used for statistical analysis. Results: Ceftazidime/avibactam susceptibility was detected in all 33 carbapenem-resistant Klebsiella spp. and 10 Pseudomonas spp. strains. Aminoglycoside resistance in Klebsiella spp. and Pseudomonas spp. was 42.4% and 50%, respectively, and fluoroquinolone resistance was 6% and 40%, respectively. Conclusion: Ceftazidime/avibactam, which is recommended for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, healthcare-associated pneumonia and ventilator-associated pneumonia, is recommended to be the primary treatment option for carbapenemase-producing strains (except metallobetalactamases) due to the susceptibility pattern found in our study.

Anahtar Kelimeler: